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Abstract
We studied whether several agents, approved or undergoing trials in human glaucoma, were eﬀective in preventing ganglion cell
loss in the DBA/2J mouse. Adult DBA/2J mice were treated with timolol, pilocarpine, brimonidine, dorzolamide, or NMDA-
receptor antagonist memantine. Surviving retinal ganglion cells of treated and control mice were retrogradely labeled with ﬂu-
orogold and counted after whole mount preparation. In treated mice, only memantine and timolol had signiﬁcant eﬀects on retinal
ganglion cell survival (P < 0:0001, analysis of variance). Brimonidine was lethal to these mice, and these retinae were not analyzed
further. The DBA/2J mouse represents a promising candidate for further experimentation in ocular hypertension.
 2002 Elsevier Science Ltd. All rights reserved.
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1. Introduction
For the past three decades, pressure-induced glau-
coma in the monkey has remained the primary animal
model of human glaucoma. Recently, much interest has
been shown in developing small animal models. Work
by multiple groups has made impressive strides in de-
veloping a rat model of ocular hypertension (Levkov-
itch-Verbin et al., 2002; Morrison, Nylander, Lauer,
Cepruna & Johnson, 1998; Neufeld, Sawada & Becker,
1999; Shareef, Garcia-Valenzuela, Salierno, Walsh &
Sharma, 1995; Yoles, Wheeler & Schwartz, 1999). Given
the wealth of knowledge about the mouse genome, as
well as the plethora of murine transgenics, a mouse
model would advance our understanding of the human
condition.
Sheldon, Warbritton, Bucci, and Turturro reported in
1995 that a strain of DBA mice could develop glauco-
matous changes under certain conditions, although they
did not note optic nerve cupping (Sheldon, Warbritton,
Bucci & Turturro, 1995). Simon John (Jackson Labo-
ratories, Maine) has reported that the DBA/2J mouse
develops essential iris atrophy, pigment dispersion, and
glaucomatous changes (including cupping) over time
(Chang et al., 1999; John et al., 1998). It was reported
recently that pigment dispersion and iris stroma atrophy
are caused by distinct mutations in genes encoding
melanosomal proteins (Anderson et al., 2001a,b). How-
ever, although these investigators have measured the
intraocular pressure in these animals, they have not
explored whether conventional glaucoma therapy could
retard the ganglion cell loss in these animals, nor have
they attempted to quantify ganglion cell survival in this
mouse strain.
The selection of suitable control animals for such
experiments is problematic. One cannot be certain that
the observed ganglion cell loss in an inherited model is
truly pressure dependent. However, Williams and co-
workers performed an exhaustive (252 mice) analysis of
ganglion cell number as a function of genetic and envi-
ronmental factors. They noted ‘‘The 82 youngest mice
(<48 days old) had an average (ganglion cell) pop-
ulation of 59,124 686 (SE), whereas the 84 oldest
mice (>180 days old) had an average population of
58,545 1027 (SE). Both groups contained a wide mix
of strains. As expected from the non-signiﬁcant diﬀer-
ence between young and old groups, the correlation
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coeﬃcient across all cases between neuron number and
age was close to zero’’ (Williams, Strom, Rice &
Goldowitz, 1996). They have generously posted the full
data set on the web (http://www.nervenet.org/main/da-
tabases.html), which allows for an estimate of normal
ganglion cell number across multiple murine strains.
Accordingly, we sought to determine whether pilo-
carpine, dorzolamide, timolol, brimonidine and me-
mantine––all agents either approved or undergoing
trials in human glaucoma––protect against ganglion cell
loss in the DBA/2J mouse.
2. Methods
All experiments were carried out in accord with the
ARVO statement for the use of animals in vision re-
search. Adult DBA/2J mice were obtained from Jackson
Laboratories (Bar Harbor, MA) at 2 months of age.
These mice were housed in a 12 h light/dark cycle with
water and food provided ad libitum. Beginning at the
age of 8 weeks, either application of commercial eye-
drops containing timolol (0.5%), pilocarpine (4%),
brimonidine (0.2%), or dorzolamide (2%), or intraperi-
toneal injections with 5 mg/kg memantine twice a day
was initiated.
After 6 months, control mice and mice of all treat-
ment groups were deeply anaesthetized with choral
hydrate (6 ml/kg body weight of a 7% solution), ad-
ministered intraperitoneally. To determine RGC densi-
ties, cells were labeled retrogradely with the ﬂuorescent
tracer Fluorogold (Molecular Probes, Eugene, Oregon)
by stereotaxic injections into both superior colliculi as
described previously (Vorwerk et al., 1996).
Two days after the superior colliculus was injected
with Fluorogold, animals were sacriﬁced by chloral
hydrate overdose. Retinae were dissected, ﬂat-mounted
on nitrocellulose ﬁlters (Sartorius, pore size 60 lm) and
ﬁxed in 2% paraformaldehyde for 30 min. Cells were
imaged under ﬂuorescence microscopy. Three areas per
retinal quadrant at three diﬀerent eccentricities of one-
sixth, one-half, and ﬁve-sixths of the retinal radius were
counted (Kl€ocker, Cellerino & B€ahr, 1998). Labeled
cells were thereby counted in 12 distinct areas of 62,500
lm2 each in each retina. Brimonidine, administered
topically, was lethal to these mice, and these retinae were
therefore not analyzed further.
To determine the age-dependency of retinal ganglion
cell loss, the number of RGC of additional untreated
mice, and mice treated with either timolol or memantine
was quantiﬁed after 4 and 9 months using the same
techniques described above.
We could not replicate the intraocular pressure
measurement technique described by John (John, Hag-
aman, MacTaggart, Peng & Smithes, 1997; John et al.,
1998). Therefore, IOP measurements in these mice are
not provided.
3. Statistical analysis
A two-way nested analysis of variance (ANOVA)
mixed model with 12 replicates for each eye was used to
assess diﬀerences in retinal ganglion cell count and
density (RGC/mm2) between eyes treated with pilocar-
pine, dorzolamide, memantine, and timolol compared to
DBA/2J controls over the ﬁrst 6 months of life. Treat-
ment eﬀects were evaluated by the F-ratio and post-hoc
Fig. 1. High power view of retrogradely labeled retinal ganglion cells
from DBA/2J mice at 6 months of age: (A) untreated, (B) treated with
timolol, (C) treated with memantine.
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Tukey method in ANOVA using a Bonferroni correc-
tion to adjust the signiﬁcance level for multiple group
comparisons among the four diﬀerent treatments (Sokal
& Rohlf, 1995). Therefore, two-tailed values of
P < 0:0125 (0.05/4) were considered statistically signiﬁ-
cant. RGC counts and densities were tested for nor-
mality using the Kolmogorov–Smirnov test and no
signiﬁcant skewness or departures from a Gaussian-
shaped distribution were found (Armitage & Berry,
1994). Therefore, continuous data are expressed in terms
of the mean and standard deviation (SD) for control and
treatment groups. Data analysis was performed using
the general linear models procedure in the SPSS soft-
ware package with group as a ﬁxed factor and eye as a
random factor (version 10.1, SPSS Inc., Chicago, IL).
4. Results
The DBA/2J mice showed a signiﬁcant age-related
decline in retinal ganglion cell number through 9 months
F ð1; 24Þ ¼ 88:11, P < 0:0001. At 4 months, DBA/2J
mice had 89 12:8 cells per ﬁeld (n ¼ 4; mean SD);
75:6 14:3 cells at 6 months, (n ¼ 10), and 40:0 9:7
per ﬁeld at 9 months (n ¼ 12).
At 6 months, eyes treated with pilocarpine had
76:3 5:1 (n ¼ 8) cells surviving while those treated
with dorzolamide had 86:4 7:7 (n ¼ 8). Animals in-
jected with memantine had 105:6 10:6 (n ¼ 8) cells
surviving and those treated with timolol had
105:5 12:9 cells surviving (n ¼ 8) (Fig. 1). Memantine
and timolol were similarly protective against ganglion
cell loss at 9 months (Fig. 3). Other drugs were not
tested beyond 6 months (illustrated in Figs. 2 and 3).
ANOVA revealed highly signiﬁcant diﬀerences be-
tween the treatment groups and control mice,
F ð4; 47Þ ¼ 12:93, P < 0:0001. Tukeys post-hoc method
indicated that the loss of ganglion cells over the ﬁrst 6
months of life was signiﬁcantly reduced in mice receiving
memantine and timolol compared to DBA/2J controls
(P < 0:0001 for each). However, no signiﬁcant diﬀer-
ences were detected in RGC survival between controls
and pilocarpine (P ¼ 0:98) or dorzolamide (P ¼ 0:32)
treatment groups (Table 1).
5. Conclusions
The DBA/2J mouse represents a promising candidate
for further experimentation in ocular hypertension, in-
asmuch as the ocular hypertension develops spontane-
ously, and leads to ganglion cell loss in a time dependent
fashion. We were able to show this continuous loss of
retinal ganglion cells during a period of 9 months.
Strikingly, the signiﬁcant age-dependent loss of RGC is
observed in 6 and 9 month old mice, at a relatively early
stage of the anatomical changes, especially if compared
to another proposed mouse model of ocular hyperten-
sion where changes are observed much later and in a
slower fashion (Anderson et al., 2001a).
Moreover, DBA/2J mice are drug responsive. The
time-dependent loss of RGC can be inhibited by either
Fig. 2. Retinal ganglion cell survival at 6 months in the DBA/2J
mouse. Values represent the mean SD. () indicates signiﬁcantly
higher RGC survival at 6 months of life for mice receiving memantine
and timolol compared to DBA/2J controls (P < 0:0001 for each) by
ANOVA. No signiﬁcant diﬀerences were detected between controls
and pilocarpine (P ¼ 0:98) or dorzolamide (P ¼ 0:32).
Fig. 3. Retinal ganglion cell survival in DBA/2J mice as a function of
age (F ð1; 24Þ ¼ 88:11, P < 0:0001) after treatment with timolol or
memantine.
Table 1
RGC survival in DBA/2J mice at 6 months
Group Number of eyes RGC/HPF
Control 10 75.3 14.3
Pilocarpine 8 76.3 5.1
Dorzolamide 8 86.4 7.7
Memantine 8 105.6 10.6a
Timolol 8 105.5 12.9a
Shown are mean number of RGC per high power field SD.
a Indicates signiﬁcantly higher survival of retinal ganglion cells for
mice treated with memantine and timolol compared to DBA/2J con-
trols (P < 0:0001 for each) by ANOVA. No signiﬁcant diﬀerences were
detected between controls and pilocarpine (P ¼ 0:98) or dorzolamide
(P ¼ 0:32).
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conventional anti-glaucomatous therapy with b-block-
ers or injections with an NMDA-receptor antagonist.
The aqueous suppressant, timolol was eﬀective in pre-
serving ganglion cell function. Timolol reduces aqueous
production, therefore it might be more suitable to a
model with blocked trabecular meshwork if compared
to medications increasing the aqueous outﬂow through
the trabecular meshwork (pilocarpine). Otherwise, dor-
zolamide, the other of the tested medications reducing
aqueous production, did not alter RGC survival.
It has been suggested that toxic levels of glutamate
might contribute to the ganglion cell loss seen in glau-
coma (Dreyer, Zurakowski, Schumer, Podos & Lipton,
1996). This raises the possibility that a glutamate an-
tagonist might be eﬃcacious in the management of this
disease. In this model, the glutamate antagonist, me-
mantine, was able to block ganglion cell loss. Meman-
tine is known to be eﬀective in rescuing ganglion cells
from chronic low dose exposure to glutamate (Vorwerk
et al., 1996). Other groups have also demonstrated that
memantine can protect retinal ganglion cells against
other injuries (Lagreze, Knorle, Bach & Feuerstein,
1998; Osborne, 1999).
In contrast, we did not observe a rescue of ganglion
cells after pilocarpine treatment. It has been previously
reported that pilocarpine might be toxic to ganglion cells
under certain conditions (Vorwerk et al., 1999). Fur-
thermore, it is not known whether the anterior segment
of the DBA/2J mouse has either receptors or the ciliary
muscle necessary for pilocarpine to eﬀectively lower
IOP. Consequently, it is not surprising that pilocarpine
was ineﬀective in this experimental model.
Dorzolamide was not statistically eﬀective at retard-
ing ganglion cell loss. As for the other pressure lowering
agents, there is no knowledge if a suitable receptor for
dorzolamide is present in the DBA/2J mouse. Also, a
recent publication shows that b-blockers are more
eﬀective in blocking voltage-dependent calcium channels
in the rat retina compared to dorzolamide and pilocar-
pine (Melena, Stanton & Osborne, 2001). This might
inﬂuence the protecting ability of dorzolamide in the
DBA/2J mouse model as well.
Given our inability to measure intraocular pressure in
these mice, as well as our limited knowledge of murine
aqueous dynamics, it is diﬃcult to assign any protective
eﬀect of these agents to their conventional mechanisms
as postulated in the human eye. Nonetheless, it is en-
couraging that the DBA/2J mouse loses ganglion cells in
a time dependent fashion faster than one might predict
in a ‘‘normal’’ mouse eye. One cannot rule out the
possibility that the ganglion cell loss seen in these mice is
unrelated to the elevated IOP reported by John et al.
(1998). However, the aqueous suppressant, timolol was
eﬀective in preserving ganglion cells. Future work will be
undertaken to determine the eﬀect of the tested medi-
cations on intraocular pressure.
The fact that brimonidine was lethal to DBA/2J mice
is slightly concerning, since this medication is in fre-
quent clinical use. Although an excellent safety proﬁle of
the drug was described (Angelov et al., 1996), there are
reports on diﬀerent severe side eﬀects in infants (Berlin
et al., 2001; Enyedi & Freedman, 2001; Korsch, Grote,
Seybold & Soditt, 1999; Walters & Taylor, 1999). It has
been suggested that brimonidine should be used with
caution in young children because of a potential de-
pression of the central nervous system (Enyedi &
Freedman, 2001). This would stand in accordance with
our results in DBA/2J mice, which might be diﬀerent to
those in control mice.
The DBA/2J mouse model proved to be a candidate
for further experimentation in ocular hypertension in-
asmuch as the DBA/2J disease process develops spon-
taneously and leads to retinal ganglion cell loss in a time
dependent fashion, which can be inhibited by IOP-
lowering or glutamate receptor blocking agents. Hope-
fully, future research will establish whether lowering the
IOP in this model can achieve good results with respect
to the preservation of ganglion cells.
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